Biogen stock surges following patent victory over Mylan for Tecfidera
pharmafile | February 6, 2020 | News story | Sales and Marketing | Biogen, Mylan, multiple sclerosis, pharma, tecfidera
Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a big win for the US firm.
The ruling means that Biogen maintain its exclusive rights to the drug until 2028. The Patent Trial and Appeal Board of the US Patent and Trademark Office judged that Mylan’s challenge had “not demonstrated by a preponderance of the evidence the unpatentability of claims”.
Biogen’s share value rocketed by 32% in the wake of the news. The gravity of the win can’t be overstated – Tecfidera brought in $4.43 billion last year, amounting to 30.8% of Biogen’s total revenue
While Biogen was reportedly pleased with the ruling, Mylan was unsurprisingly unhappy, with a company spokesperson noting that the firm “strongly disagrees with the decision and plans to pursue all available options for appeal.”
“Mylan continues to believe, based on the law and the facts, that Biogen’s ‘514 patent is invalid and will continue its challenges in both the district court and the Federal Circuit to remove this patent from blocking generic competition to Tecfidera,” they continued.
Matt Fellows
Related Content
Eisai shares new data for Leqembi for Alzheimer’s treatment
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …
Biogen’s biosimilar Tofidence approved by FDA
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …